Despite the massive global spend on biology-driven drug discovery, tackling side effects and adverse events resulting from drug promiscuity is one of the greatest challenges faced today.

We have proposed an original solution to this persistent problem and hold a patented technology and relevant know-how in R&D of tailor-made oligonucleotide therapeutics that provide exclusive therapeutic intervention against their molecular targets thereby eliminating treatment-induced toxicity. We are committed to encouraging the translation of these discoveries into new treatments and pursue milestone-driven projects. Based on this proprietary platform, named ESiNAR-X^®, multiple therapeutic leads have been proposed for various diagnoses and are currently in different stages of preclinical development.